LBA4: Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): Updated overall survival (OS) analysis from the LAURA study
Sundar Ramalingam, Mustafa Özgüroğlu, M-J. Ahn, Xiaorong Dong, J.C-H. Yang, S. Oizumi, Keisuke Goto, M.A. Cobo Dols, S-W. Kim, T-C. Hsia, Jarin Chindaprasirt, Fumihiro Fujiki, Niki Lama, Ignacio Casarini, T. Kato, X. Huang, Annette Evans, Ana Bolanos, Shun Lü
Topics & Concepts
MedicineOsimertinibChemoradiotherapyOncologyInternal medicineStage (stratigraphy)non-small cell lung cancer (NSCLC)Lung cancerOverall survivalCancerEpidermal growth factor receptorA549 cellErlotinibPaleontologyBiologyLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentGastric Cancer Management and Outcomes